Manufacturing Sites

Our thirteen separate production plants have been designed to fully comply with the current regulations for Good Manufacturing Practice (GMP) of the European Union and the World Health Organization (WHO).


At the AZ factory we can produce and pack 1.5 billion tablets and 300 million capsules per year. Our injectables plant of cephalosporins is built online from the washing of the vials and sterilisation units to the filling stage to rubber stoppering of the vials, capping, labeling and final packaging.

Our latest injectables manufacturing plant in Cyprus is for ampoules. It has a production and packing capacity of 40 million ampoules for injection per year. In our factory in the Netherlands we develop oral dosage forms. We also sell dossiers to third parties for registration in other EU and non-EU territories.

Our dry powder inhaler (DPI) facility Andi-Ventis is dedicated to the production of DPIs in a state-of-the-art facility. Here, we develop powders for inhalation used for the treatment of asthma in our own R&D department.

We manufacture oral cephalosporins as well as oral and injectable penicillins in separate manufacturing plants.

Our latest strategic investments are the new manufacturing plants in Vietnam. The first one is now operating in full compliance with European standards. It was built to produce solid dosage forms with a capacity of 2 billion tablets and 600 million capsules per year. The other two manufacturing plants are under construction and will start the production of gels, creams, ointments, syrups and injectable cephalosporins (powder for injection/infusion) in their state-of-the-art facilities by the end of 2016.